226 related articles for article (PubMed ID: 10401563)
21. Effect of the tachykinin NK1 receptor antagonists, RP 67580 and SR 140333, on electrically-evoked substance P release from rat spinal cord.
Malcangio M; Bowery NG
Br J Pharmacol; 1994 Oct; 113(2):635-41. PubMed ID: 7530576
[TBL] [Abstract][Full Text] [Related]
22. Pharmacological evidence that NK-2 tachykinin receptors mediate hypotension in the guinea pig but not in the rat.
Floch A; Thiry C; Cavero I
Fundam Clin Pharmacol; 1996; 10(4):337-43. PubMed ID: 8871132
[TBL] [Abstract][Full Text] [Related]
23. Pharmacological characterization of LY303870: a novel, potent and selective nonpeptide substance P (neurokinin-1) receptor antagonist.
Gitter BD; Bruns RF; Howbert JJ; Waters DC; Threlkeld PG; Cox LM; Nixon JA; Lobb KL; Mason NR; Stengel PW
J Pharmacol Exp Ther; 1995 Nov; 275(2):737-44. PubMed ID: 7473161
[TBL] [Abstract][Full Text] [Related]
24. SR 140333, a novel, selective, and potent nonpeptide antagonist of the NK1 tachykinin receptor: characterization on the U373MG cell line.
Oury-Donat F; Lefevre IA; Thurneyssen O; Gauthier T; Bordey A; Feltz P; Emonds-Alt X; Le Fur G; Soubrie P
J Neurochem; 1994 Apr; 62(4):1399-407. PubMed ID: 7510780
[TBL] [Abstract][Full Text] [Related]
25. NK1 receptor-mediated endothelium-dependent relaxation and contraction with different sensitivity to post-receptor signaling in pulmonary arteries.
Miike T; Shirahase H; Kanda M; Kunishiro K; Kurahashi K
Vascul Pharmacol; 2009; 51(2-3):147-53. PubMed ID: 19539781
[TBL] [Abstract][Full Text] [Related]
26. Electrophysiological characterisation of tachykinin receptors in the rat nucleus of the solitary tract and dorsal motor nucleus of the vagus in vitro.
Maubach KA; Jones RS
Br J Pharmacol; 1997 Nov; 122(6):1151-9. PubMed ID: 9401780
[TBL] [Abstract][Full Text] [Related]
27. Upregulation of tachykinin NK-1 and NK-3 receptor binding sites in the spinal cord of spontaneously hypertensive rat: impact on the autonomic control of blood pressure.
Cloutier F; Ongali B; Deschamps K; Brouillette J; Neugebauer W; Couture R
Br J Pharmacol; 2006 May; 148(1):25-38. PubMed ID: 16491095
[TBL] [Abstract][Full Text] [Related]
28. Septide but not substance P stimulates inhibitory neurons in guinea-pig ileum.
Burcher E; Stamatakos C
Eur J Pharmacol; 1994 Jun; 258(3):R9-10. PubMed ID: 7522175
[TBL] [Abstract][Full Text] [Related]
29. Evidence for a GABA(B) receptor component in the spinal action of Substance P (SP) on arterial blood pressure in the awake rat.
Brouillette J; Couture R
Br J Pharmacol; 2002 Aug; 136(8):1169-77. PubMed ID: 12163350
[TBL] [Abstract][Full Text] [Related]
30. Neurokinin receptors (NK1, NK2) in the mouse: a pharmacological study.
Nsa Allogho S; Nguyen-Le XK; Gobeil F; Pheng LH; Regoli D
Can J Physiol Pharmacol; 1997 Jun; 75(6):552-7. PubMed ID: 9276127
[TBL] [Abstract][Full Text] [Related]
31. Opioid activity of sendide, a tachykinin NK1 receptor antagonist.
Sakurada T; Yuhki M; Inoue M; Sakurada C; Tan-No K; Ohba M; Kisara K; Sakurada S
Eur J Pharmacol; 1999 Mar; 369(3):261-6. PubMed ID: 10225361
[TBL] [Abstract][Full Text] [Related]
32. In vitro and in vivo biological activities of SR140333, a novel potent non-peptide tachykinin NK1 receptor antagonist.
Emonds-Alt X; Doutremepuich JD; Heaulme M; Neliat G; Santucci V; Steinberg R; Vilain P; Bichon D; Ducoux JP; Proietto V
Eur J Pharmacol; 1993 Dec; 250(3):403-13. PubMed ID: 7509286
[TBL] [Abstract][Full Text] [Related]
33. Temperature and agonist dependency of tachykinin NK1 receptor antagonist potencies in rat isolated superior cervical ganglion.
Hawcock AB; Beresford IJ; Marshall FH; Hagan RM
Eur J Pharmacol; 1995 Dec; 294(1):163-71. PubMed ID: 8788428
[TBL] [Abstract][Full Text] [Related]
34. Distribution of Fos-like immunoreactivity in guinea-pig brain following administration of the neurokinin-1 receptor agonist, [SAR9,MET(O2)11]substance P.
Yip J; Chahl LA
Neuroscience; 1999; 94(2):663-73. PubMed ID: 10579226
[TBL] [Abstract][Full Text] [Related]
35. Senktide-induced gerbil foot tapping behaviour is blocked by selective tachykinin NK1 and NK3 receptor antagonists.
Sundqvist M; Kristensson E; Adolfsson R; Leffler A; Ahlstedt I; Engberg S; Drmota T; Sigfridsson K; Jussila R; de Verdier J; Novén A; Johansson A; Påhlman I; von Mentzer B; Lindström E
Eur J Pharmacol; 2007 Dec; 577(1-3):78-86. PubMed ID: 17920583
[TBL] [Abstract][Full Text] [Related]
36. Neuropharmacological characterization of SR 140333, a non peptide antagonist of NK1 receptors.
Jung M; Calassi R; Maruani J; Barnouin MC; Souilhac J; Poncelet M; Gueudet C; Emonds-Alt X; Soubrié P; Brelière JC
Neuropharmacology; 1994 Feb; 33(2):167-79. PubMed ID: 8035902
[TBL] [Abstract][Full Text] [Related]
37. Comparison of antagonistic effects of sendide and CP-96,345 on a spinally mediated behavioural response in mice.
Sakurada T; Manome Y; Katsumata K; Tan-No K; Sakurada S; Ohba M; Kisara K
Eur J Pharmacol; 1994 Aug; 261(1-2):85-90. PubMed ID: 7528145
[TBL] [Abstract][Full Text] [Related]
38. Effect of tachykinin receptor inhibition in the brain on cardiovascular and behavioral responses to stress.
Culman J; Klee S; Ohlendorf C; Unger T
J Pharmacol Exp Ther; 1997 Jan; 280(1):238-46. PubMed ID: 8996202
[TBL] [Abstract][Full Text] [Related]
39. Different susceptibility to neurokinin 1 receptor antagonists of substance P and septide-induced interleukin-6 release from U373 MG human astrocytoma cell line.
Palma C; Goso C; Manzini S
Neurosci Lett; 1994 Apr; 171(1-2):221-4. PubMed ID: 7521949
[TBL] [Abstract][Full Text] [Related]
40. Further evidence for the presence of "septide-sensitive" tachykinin binding sites in tissues possessing solely NK(1) tachykinin receptors.
Torrens Y; Beaujouan JC; Saffroy M; Glowinski J
Biochem Biophys Res Commun; 2000 Apr; 270(2):668-72. PubMed ID: 10753681
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
